Academic Journal
Q1Amyloid
About Amyloid
Amyloid is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q1, with an SJR of 2.194 and H-index of 82.
Coverage: 1994-2026. Research categories: Internal Medicine (Q1); Medicine (miscellaneous) (Q1).
Verified field sources
- Journal Impact Factor: 5.1 — Official source; checked 2026-10-03. Publisher-reported Journal Impact Factor and year from Taylor & Francis About this journal information.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Publisher-reported Journal Impact Factor and year from Taylor & Francis About this journal information.
Source-backed journal facts
Topics in published research
Amyloidosis: Diagnosis, Treatment, Outcomes; Alzheimer's disease research and treatments; Parathyroid Disorders and Treatments; Dermatological and Skeletal Disorders; Protein Kinase Regulation and GTPase Signaling; Cellular transport and secretion.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Cryo-EM reveals untwisted and non-periodic twist fibrils in ex vivo type B ATTRv-V30M fibrils
Shumaila Afrin, Maria del Carmen Fernandez-Ramirez, Binh An Nguyen, Saylor Schreiber et al.
2026-09-30 · DOI: 10.1080/13506129.2026.2738161Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis
Amaury Broussier, Amira Zaroui, Mounira Kharoubi, Silvia Oghina et al.
2026-09-10 · DOI: 10.1080/13506129.2026.2729446Sodium-glucose cotransporter-2 inhibitor therapy and body composition analysis in transthyretin amyloid cardiomyopathy: a prospective, feasibility pilot study
Ani Nalbandian, Sergio Teruya, Dia Smiley, Stephen Helmke et al.
2026-09-08 · DOI: 10.1080/13506129.2026.2727117Liver stiffness in AL amyloidosis: interest in diagnosis and prognosis
Paul Carrier, Véronique Loustaud-Ratti, Jean-François Cadranel, Céline Rigaud et al.
2026-09-06 · DOI: 10.1080/13506129.2026.2725750Susceptibility and screening approaches in systemic amyloidosis: expert perspectives from the International Society of Amyloidosis (ISA)
Taxiarchis Kourelis, Raymond Comenzo, Andrea Cortese, Justin L. Grodin et al.
2026-09-04 · DOI: 10.1080/13506129.2026.2718204Gastric amyloid pathology and mucosal denervation in ATTRv amyloidosis: insights from patients, mice, and gut microenvironment profiles
Hsueh-Wen Hsueh, Ping-Hao Yang, Ping-Huei Tseng, Ti-Yen Yeh et al.
2026-08-29 · DOI: 10.1080/13506129.2026.2723933Hereditary ATTR amyloidosis with prominent central nervous system involvement associated with the p.Arg54Gly (Arg34Gly) substitution
Consuelo Ciprietti, Mirella Russo, Giuliano F. Patanè, Loris Di Clemente et al.
2026-08-26 · DOI: 10.1080/13506129.2026.2719698Selective cellular vulnerability and resilience in amyloidosis: insights from the 2025 International Society of Amyloidosis Workshop
Giampaolo Merlini
2026-08-12 · DOI: 10.1080/13506129.2026.2714521Clinical significance of gastric food residue in gastrointestinal hereditary transthyretin amyloidosis
Takuma Okamura, Yugo Iwaya, Nagaaki Katoh, Yoshiki Sekijima et al.
2026-08-04 · DOI: 10.1080/13506129.2026.2711435Diagnostic utility of deep excisional skin biopsy including abdominal fat for transthyretin cardiac amyloidosis
Kohei Honda, Ikoi Omatsu, Tetsuhiro Yamano, Hironobu Naiki et al.
2026-07-30 · DOI: 10.1080/13506129.2026.2711143Progressive leptomeningeal involvement on gadolinium-enhanced FLAIR MRI in hereditary transthyretin amyloidosis with the V30M (p.V50M) mutation
Yohei Misumi, Toshiya Nomura, Tomoaki Taguchi, Shiori Yamakawa et al.
2026-07-17 · DOI: 10.1080/13506129.2026.2702928Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study
Marcus A. Urey, Quan M. Bui, Laura Obici, Jonas Wixner et al.
2026-07-17 · DOI: 10.1080/13506129.2026.2695367Hepatic multimodal phenotyping in AL amyloidosis with cardiac involvement: the D-Amy-LIPHE study
Anna Sessa, Amira Zaroui, Margaux Charles, Stefano Caruso et al.
2026-07-06 · DOI: 10.1080/13506129.2026.2694403Guidelines for the management of hereditary ATTR amyloidosis 2026
Yoshiki Sekijima, Mitsuharu Ueda, John L. Berk, Laura Obici et al.
2026-07-03 · DOI: 10.1080/13506129.2026.2695368Article commentary on: ‘Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study’
Christian Messina
2026-07-03 · DOI: 10.1080/13506129.2026.2726463Proteostasis is disrupted in human endothelial cells by serum from ATTR patients and is rescued by tafamidis treatment
Despoina D. Gianniou, Dimitrios Delialis, Georgios Georgiopoulos, Dimitrios Bampatsias et al.
2026-06-26 · DOI: 10.1080/13506129.2026.2689643Fat aspiration for amyloidosis screening of 2830 patients from 2013 to 2020: compelling sensitivity for AL and better sensitivity in females for all major subtypes
Christoph Richard Kimmich, Stefan O. Schönland, Norbert Blank, Tobias Dittrich et al.
2026-07-03 · DOI: 10.1080/13506129.2026.2685673Exploring light chain cardiotoxicity in AL amyloidosis: impact on hiPSC-derived cardiomyocyte activity
Serena Calamaio, Anthony Frosio, Dario Melgari, Luca Broggini et al.
2026-07-03 · DOI: 10.1080/13506129.2026.2686787Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension
Cécile Cauquil, David Adams, Julian Gillmore, Alejandra Gonzalez-Duarte et al.
2026-07-03 · DOI: 10.1080/13506129.2026.2685666Fluorine-18 florbetapir positron emission tomography unmasks amyloidosis with equivocal technetium-99m pyrophosphate findings driven by a novel transthyretin variant
Xinglin Yang, Xuezhu Wang, Yuke Zhang, Xuemei Wang et al.
2026-06-12 · DOI: 10.1080/13506129.2026.2676849Reviews
Community Reviews
Version History
September 23, 2026 at 8:49 pm
September 23, 2026